Iadademstat + SBRT With Atezo in ES-SCLC

This is a phase 1b dose escalation, open-label, non-randomized study of participants with residual, progressive or recurrent ES-SCLC who previously received platinum-based chemotherapy with or without immune checkpoint inhibitor therapy; participants who have achieved only stable disease at the completion of initial platinum-based treatment are eligible for enrollment.

Trial Details

NCT ID
NCT07113691
Phase
PHASE1
Sponsor
Yale University
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Iadademstat
  • Atezolizumab
  • SBRT
Locations (sample)
  • New Haven, Connecticut, United States|41.30815,-72.92816

Key Eligibility Criteria

  • Signed informed consent form.
  • Ability to comply with protocol, in the treating investigator's judgment.
  • Age 18 years or older.
  • Participant must have a body weight of at least 50 Kg.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →